Teva and MedinCell Announce Positive Results for Registration Trial of Investigational Extended-Release Subcutaneous Injectable Risperidone for Patients with Schizophrenia
Teva and MedinCell Announce Positive Results for Registration Trial of Investigational Extended-Release Subcutaneous Injectable Risperidone for Patients with Schizophrenia
January 7, 2021
Previous PostMedinCell announces the resume of listing of its shares on Euronext Paris as of the opening of the stock exchange tomorrow
Next PostMedinCell announces the transfer of its shares from compartment C to compartment B of Euronext Paris
